Sanofi logo

SanofiNASDAQ: SNY

Profile

Sector:

Healthcare

Country:

France

IPO:

01 July 2002

Next earnings report:

31 January 2025

Last dividends:

09 May 2024

Next dividends:

N/A
$134.03 B
-8%vs. 3y high
99%vs. sector
-12%vs. 3y high
48%vs. sector
-vs. 3y high
-vs. sector
-33%vs. 3y high
43%vs. sector

Price

after hours | Thu, 31 Oct 2024 23:47:08 GMT
$53.46-$0.54(-1.00%)
$15.57 B$12.68 B
$15.57 B$3.10 B

Analysts recommendations

Institutional Ownership

SNY Latest News

Sanofi Cancels Consumer Healthcare Business Spin-Off
forbes.com30 October 2024 Sentiment: NEUTRAL

Deal Overview

Resalis Therapeutics Gains Strategic Equity Investment from Sanofi
businesswire.com28 October 2024 Sentiment: POSITIVE

TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010, through a Phase 2 proof-of-concept clinical trial. RES-010 represents a first-in-class antisense oligonucleotide targeting miR-22, a non-coding RNA that plays a pivotal role in the molecular pathways underlying obesity. This innovative approach positions Resalis to pot.

Why Sanofi Stock Flew Higher on Friday
fool.com25 October 2024 Sentiment: POSITIVE

No investor can ignore a crushing bottom-line beat and raised profitability guidance.

Sanofi (SNY) Q3 2024 Earnings Call Transcript
seekingalpha.com25 October 2024 Sentiment: POSITIVE

Sanofi (NASDAQ:SNY ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Thomas Kudsk - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research and Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Brendan O'Callaghan - Executive Vice President, Manufacturing and Supply Roy Papatheodorou - Executive Vice President, General Counsel Conference Call Participants Richard Vosser - JPMorgan Emily Field - Barclays Graham Parry - BofA Seamus Fernandez - Guggenheim Jo Walton - UBS Peter Welford - Jefferies Luisa Hector - Berenberg Thibault Boutherin - Morgan Stanley Simon Baker - Redburn Steve Scala - TD Cowen David Risinger - Leerink Richard Parkes - BNP Exane Rajesh Kumar - HSBC Eric Berrigaud - Stifel Florent Cespedes - Bernstein Thomas Kudsk Welcome to the Q3 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com.

Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
zacks.com25 October 2024 Sentiment: POSITIVE

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
benzinga.com25 October 2024 Sentiment: POSITIVE

On Friday, Sanofi SA SNY reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency.

Sanofi Q3 earnings beat market view, boosted by vaccine sales
reuters.com25 October 2024 Sentiment: POSITIVE

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
globenewswire.com25 October 2024 Sentiment: POSITIVE

Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance

French govt set to take stake in Sanofi unit after PE sale
proactiveinvestors.co.uk21 October 2024 Sentiment: POSITIVE

France is reportedly set to acquire a small stake in Sanofi SA's (ADR) (NYSE:SNY) consumer healthcare unit as the pharmaceutical company proceeds with a €16 billion deal to sell half of the business to US private equity firm Clayton, Dubilier & Rice (CD&R), despite political opposition. Sanofi entered exclusive talks with CD&R to sell 50% of Opella, the division behind well-known products like Doliprane, a popular painkiller in France.

Sanofi enters exclusive talks with CD&R for Opella sale
reuters.com21 October 2024 Sentiment: POSITIVE

Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).

What type of business is Sanofi?

Sanofi is an international pharmaceutical company based in Paris, France. The company was founded in 1973. Initially, it was one of the divisions of the Elf Aquitane company (petrochemical industry). In 1979, it was formed as a separate full-fledged pharmaceutical company. Sanofi produces vaccines, general medicines, products for the treatment of diabetes and cardiovascular diseases, and veterinary products. The company also has divisions that focus on innovative biotechnologies and research in the healthcare field (oncology, immunology, multiple sclerosis, rare diseases). The R&D (research and development) segment is well developed - with around 100 active development projects; around 40 projects are in the final stages or approved.

What sector is Sanofi in?

Sanofi is in the Healthcare sector

What industry is Sanofi in?

Sanofi is in the Drug Manufacturers - General industry

What country is Sanofi from?

Sanofi is headquartered in France

When did Sanofi go public?

Sanofi initial public offering (IPO) was on 01 July 2002

What is Sanofi website?

https://www.sanofi.com

Is Sanofi in the S&P 500?

No, Sanofi is not included in the S&P 500 index

Is Sanofi in the NASDAQ 100?

No, Sanofi is not included in the NASDAQ 100 index

Is Sanofi in the Dow Jones?

No, Sanofi is not included in the Dow Jones index

When was Sanofi the previous earnings report?

No data

When does Sanofi earnings report?

The next expected earnings date for Sanofi is 31 January 2025